• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»ophthalmic devices

LensOne enters pivotal study as Long Bridge Medical targets a difficult gap in secondary IOL fixation

By Pallavi Madhiraju on March 27, 2026   Medical Devices & Diagnostics  

LensOne enters pivotal study as Long Bridge Medical targets a difficult gap in secondary IOL fixation

Long Bridge Medical’s LensOne has entered a pivotal FDA-cleared study. Read why this ophthalmic device trial could reshape secondary IOL fixation.

Why Alcon’s TOTAL30 Multifocal for Astigmatism targets the toughest segment in contact lens care

By Pallavi Madhiraju on February 19, 2026   Medical Devices & Diagnostics  

Why Alcon’s TOTAL30 Multifocal for Astigmatism targets the toughest segment in contact lens care

Alcon has launched TOTAL30 Multifocal for Astigmatism in the U.S. Find out why this matters for presbyopia care and contact lens adoption.

Recent Posts

  • Can Pfizer’s $10.5bn Innovent deal rebuild confidence in its oncology pipeline?
  • Nuvalent’s ALK inhibitor gets Priority Review as lung cancer treatment sequencing evolves
  • Can Eli Lilly’s $3bn Haisco deal deepen big pharma’s China drug discovery pipeline?
  • Cirius Therapeutics puts CIR-0602K in the spotlight as ADA 2026 turns to metabolic complexity
  • AstraZeneca’s Imfinzi gains a first-mover edge in high-risk non-muscle-invasive bladder cancer
  • Can Ono and Deciphera turn ONO-4578 into a global Phase 3 oncology contender?
  • Ranok Therapeutics pushes RNK08954 forward as KRAS G12D drug development heats up
  • Can Servier’s $2.65bn Edgewise deal reshape the muscular dystrophy drug race?
  • Can Convergent Therapeutics define the next prostate cancer standard after Lu-PSMA therapy?
  • Why T-CURX’s Pantherna acquisition could matter for the future of cell therapy manufacturing
  • Is Amgen’s bispecific lung cancer drug becoming a global standard after chemotherapy failure?
  • Fulgent Genetics’ oncology pivot gets sharper as FID-007 shows Phase 2 activity at ASCO 2026
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes